

Bombshell Document Dump on Pfizer Vaccine Data

By Prof Michel Chossudovsky

Global Research, December 07, 2022

Region: <u>USA</u>

Theme: Media Disinformation, Science and

Medicine

All Global Research articles can be read in 51 languages by activating the "Translate Website" drop down menu on the top banner of our home page (Desktop version).

To receive Global Research's Daily Newsletter (selected articles), click here.

Visit and follow us on Instagram at @crg_globalresearch.

First published on December 5, 2021, updated December 18, 2021.

Since publication, important new sections of this confidential Pfizer report have been released.

"Have you seen the document dump on the Pfizer vaccine data? It's a bombshell. No wonder the FDA fought to keep it hidden for 55 years.

Here is the quick takeaway:

By February of 2021, Pfizer had already received more than 1,200 reports of deaths allegedly caused by the vaccine and tens of thousands of reported adverse events, including 23 cases of spontaneous abortions out of 270 pregnancies and more than 2,000 reports of cardiac disorders.

Bear in mind, this is Pfizer's own data." Election Wizard

This Confidential Pfizer Report released as part of a Freedom of Information (FOI) procedure provides data on deaths and adverse events recorded by Pfizer from the outset of the vaccine project in December 2020 to the end of February 2021, namely a very short period (at most two and a half months).

The Pfizer BioNTech vaccine was launched in the US on the 14th of December after the granting of Emergency Use Authorization on December 11, 2020.

In a twisted irony, the data revealed in this "insider report" refutes the official vaccine narrative peddled by the governments and the WHO. It also confirms the analysis of numerous medical doctors and scientists who have revealed the devastating consequences

of the mRNA "vaccine".

What is contained in Pfizer's "confidential" report is detailed evidence on the impacts of the "vaccine" on mortality and morbidity. This data which emanates from the "Horse's Mouth" can now be used to confront as well formulate legal procedures against Big Pharma, the governments, the WHO and the media.

In a Court of Law, the **evidence contained in this Big Pharma confidential report** (coupled with the data on deaths and adverse events compiled by the national authorities in the EU, UK and US) is irrefutable: because it is their data and their estimates and not ours.



Bear in mind: it's data which is based on reported and recorded cases, which constitute a small percentage of the actual number of vaccine related deaths and adverse events.

This is a de facto Mea Culpa on the part of Pfizer. #Yes it is a Killer Vaccine

Pfizer was fully aware that the mRNA vaccine which it is marketing Worldwide would result in a wave of mortality and morbidity. This is tantamount to a crime against humanity on the part of Big Pharma.

Pfizer knew from the outset that it was a killer vaccine.

It is also a Mea Culpa and Treason on the part of corrupt national governments Worldwide which are being threatened and bribed by Big Pharma.

Video Interview with Michel Chossudovsky on the The Secret Pfizer Report

Click right corner to access fullscreen

No attempt has been made by the governments to call for the withdrawal of the killer vaccine.

People are told that the vaccine is intended to save lives.

"Killing is Good for Business": It is a multibillion dollar operation worldwide. And Pfizer already has a <u>criminal record (2009) with the US Department of Justice on charges of "fraudulent marketing"</u>.

We invite the "Covid-19 Fact Checkers" to peruse this Confidential Pfizer report.

(Oops. It just so happens that Reuters "Fact Checker" chairman and former Chief Executive Officer (CEO) James C. Smith "is also a top <u>investor</u> and <u>board member</u> of Pfizer". "No

Conflict of Interest").

Selected excerpts, tables and diagram from the Report below

Michel Chossudovsky.

Global Research, December 5, 2021, Update with Video Interview on May, 17, 2022

See author's **Biographical Note**

Archive of Articles on Global Research

Please forward this article

Click here to read the complete Pfizer report.

also see details in the Appendices

Selected Excerpts of the Report

BNT162b2

5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports

5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021

This document provides an integrated analysis of the cumulative post-authorization safety data, including U.S. and foreign post-authorization adverse event reports received through 28 February 2021.

(...)

Pfizer is responsible for the management post-authorization safety data on behalf of the MAH BioNTech according to the Pharmacovigilance Agreement in place. Data from BioNTech are included in the report when applicable.

Reports are submitted voluntarily, and the magnitude of underreporting is unknown.

(...)

Cumulatively, through 28 February 2021 [in less than three months], there was a total of 42,086 case reports (25,379 medically confirmed and 16,707 non-medically confirmed) containing 158,893 events. Most cases (34,762) were received from United States (13,739), United Kingdom (13,404) Italy (2,578), Germany (1913), France (1506), Portugal (866) and Spain (756); the remaining 7,324 were distributed among 56 other countries.

(...)

As shown in Figure 1 [see below], the System Organ Classes (SOCs) that contained the greatest number (≥2%) of events, in the overall dataset, were General disorders and administration site conditions (51,335 AEs), Nervous system disorders (25,957), Musculoskeletal and connective tissue disorders (17,283), Gastrointestinal disorders (14,096), Skin and subcutaneous tissue disorders (8,476), Respiratory, thoracic and mediastinal disorders (8,848), Infections and infestations (4,610), Injury, poisoning and procedural complications (5,590), and Investigations (3,693

emphasis added

Figure 1. Total Number of BNT162b2 AEs by System Organ Classes and Event Seriousness




Table 1. General Overview: Selected Characteristics of All Cases Received During the Reporting Interval

Characteristics		Relevant cases (N=42086)
Gender:	Female	29914
	Male	9182
	No Data	2990
Age range (years):	≤ 17	175ª
0.01 -107 years Mean = 50.9 years n = 34952	18-30	4953
	31-50	13886
	51-64	7884
	65-74	3098
	≥ 75	5214
	Unknown	6876
Case outcome:	Recovered/Recovering	19582
	Recovered with sequelae	520
	Not recovered at the time of report	11361
	Fatal	1223
	Unknown	9400

a. in 46 cases reported age was <16-year-old and in 34 cases <12-year-old.

Table 2. Events Reported in ≥2% Cases

MedDRA SOC	MedDRA PT	Cumulatively Through 28 February 2021 AEs (AERP%) N = 42086
Blood and lymphatic system disorders		14 42000
	Lymphadenopathy	1972 (4.7%)
Cardiac disorders		
	Tachycardia	1098 (2.6%)
Gastrointestinal disorders		
	Nausea	5182 (12.3%)
	Diarrhoea	1880 (4.5%)
	Vomiting	1698 (4.0%)
General disorders and adminis	tration site conditions	
	Pyrexia	7666 (18.2%)
	Fatigue	7338 (17.4%)
	Chills	5514 (13.1%)
	Vaccination site pain	5181 (12.3%)

Table 7. AESIs Evaluation for BNT162b2

AESIs ^a	Post-Marketing Cases Evaluation ^b
Category	Total Number of Cases (N=42086)
Anaphylactic Reactions Search criteria: Anaphylactic reaction SMQ (Narrow and Broad, with the algorithm applied), selecting relevant cases according to BC criteria	Please refer to the Risk 'Anaphylaxis' included above in Table 4.
Cardiovascular AESIs Search criteria: PTs Acute myocardial infarction; Arrhythmia; Cardiac failure; Cardiac failure acute; Cardiogenic shock; Coronary artery disease; Myocardial infarction; Postural orthostatic tachycardia syndrome; Stress cardiomyopathy; Tachycardia	 Number of cases: 1403 (3.3% of the total PM dataset), of which 241 are medically confirmed and 1162 are non-medically confirmed; Country of incidence: UK (268), US (233), Mexico (196), Italy (141), France (128), Germany (102), Spain (46), Greece (45), Portugal (37), Sweden (20), Ireland (17), Poland (16), Israel (13), Austria, Romania and Finland (12 each), Netherlands (11), Belgium and Norway (10 each), Czech Republic (9), Hungary and Canada (8 each), Croatia and Denmark (7 each), Iceland (5); the remaining 30 cases were distributed among 13 other countries; Subjects' gender: female (1076), male (291) and unknown (36); Subjects' age group (n = 1346): Adult^c (1078), Elderly^d (266) Child^c and Adolescent^f (1 each); Number of relevant events: 1441, of which 946 serious, 495 non-serious; in the cases reporting relevant serious events; Reported relevant PTs: Tachycardia (1098), Arrhythmia (102), Myocardial infarction (89), Cardiac failure (80), Acute myocardial infarction (41), Cardiac failure acute (11), Cardiogenic shock and Postural orthostatic tachycardia syndrome (7 each) and Coronary artery disease (6); Relevant event onset latency (n = 1209): Range from <24 hours to 21 days, median <24 hours;

Click here to read

Pfizer's report.

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums, etc.

Featured image is from BigPharmaNews.com

The original source of this article is Global Research Copyright © Prof Michel Chossudovsky, Global Research, 2022

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: Prof Michel Chossudovsky

About the author:

Michel Chossudovsky is an award-winning author, Professor of Economics (emeritus) at the University of Ottawa, Founder and Director of the Centre for Research on Globalization (CRG), Montreal, Editor of Global Research. He has taught as visiting professor in Western Europe, Southeast Asia, the Pacific and Latin America. He has served as economic adviser to governments of developing countries and has acted as a consultant for several international organizations. He is the author of 13 books. He is a contributor to the Encyclopaedia Britannica. His writings have been published in more than twenty languages. In 2014, he was awarded the Gold Medal for Merit of the Republic of Serbia for his writings on NATO's war of aggression against Yugoslavia. He can be reached at crgeditor@yahoo.com

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca